Developer docs
API playgroundTry for free, no card

Search company profiles

General Genomics Inc.

Full company profile

uuid0003fcw

Namestring
General Genomics Inc.
Legal namestring
General Genomics, Inc.
Websiteurl
ggenomics.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

General Genomics Inc. is a privately held, Service-Disabled Veteran-Owned Small Business founded in 2020 and headquartered in Oklahoma City, with a wholly-owned subsidiary (General Genomics AI / GGAI) in Fort Worth, TX. The company develops AI/ML-powered bioinformatics software that combines proprietary machine learning models, large language models, predictive analytics, and synthetic data generation to analyze biological and man-made systems for government and commercial clients. Its product portfolio centers on three core platforms: Curo46™, an AI analytics platform for predictive health risk management, biosecurity threat assessment, and operational readiness; CuroSygnal, an explainable AI clinical decision support tool deployed in skilled nursing and post-acute care to surface return-to-hospital risk 3-14 days in advance; and SYN46™, which generates virtual patient models and downloadable de-identified datasets for privacy-compliant research and analytics. The company also offers EdTech and professional development training, a forthcoming Data Portal for synthetic data distribution, custom informatics solutions, and NAICS-aligned federal procurement services.

The firm pursues a direct enterprise sales motion targeting federal, state, and local government agencies (across DOD, HHS, DHS, Intel Community, USDA, FDA, and NASA) alongside commercial customers in healthcare providers, pharmaceuticals, insurance, sports medicine, and academic research. It relies on SDVOSB set-aside procurement advantages, NAICS code alignment, and compliance postures covering HIPAA, GDPR, and FDA 21 CFR Part 11 (clinical decision support exemption). CuroSygnal is natively integrated with the MatrixCare EHR and supports Microsoft single sign-on.

General Genomics generates revenue through platform licensing and subscriptions (Curo46™, CuroSygnal), synthetic and de-identified data products (SYN46™, forthcoming Data Portal), and professional services including custom AI/ML integration and workforce training. The company has raised approximately $4.95M across three funding rounds (2020, 2021, May 2024), holds one granted U.S. patent plus two pending patents on ML-driven disease prediction and treatment recommendation, and operates with an 11-50 employee team led by CEO & Founder AJ Rosenthal, COO & VP of Growth & EdTech Dr. Chris Naler (Col. USMC Ret.), and Director of Machine Learning Dr. Shannon Schlueter.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOklahoma City, United States
HQ citystring
Oklahoma City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
predictive analytics, synthetic data, bioinformatics platforms, clinical decision support, genomic risk prediction
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI/ML Bioinformatics Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1AI/ML Platform Licensing and Subscriptions
TypeSubscription Recurring
Description

Revenue generated from licensing proprietary AI platforms including Curo46™ and CuroSygnal to government and commercial clients. Solutions are tailored to organization-specific needs with custom implementation and ongoing support.

ggenomics.com
2Synthetic and De-identified Data Products
TypeSubscription Recurring
Description

Revenue from providing synthetic data (SYN46™) and de-identified datasets through the Data Portal for healthcare, research, and commercial applications.

ggenomics.com
3Professional Services and Consulting
TypeProfessional Services
Description

Custom AI/ML integration, workflow optimization, and professional development training services. Includes sector-specific training programs for government and commercial sectors.

ggenomics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Demo evaluation available
ModelOtherBilling cadencePay-as-you-go
Notes

30-minute working demo with Curo46 product or sales lead available for platform evaluation before commitment.

ggenomics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Curo46™
Description

AI-powered platform designed to drive innovation in bioscience and data solutions, providing predictive health risk management, supply chain optimization, and advanced cybersecurity measures.

ggenomics.com
+3 more records
Core offering1 text field

General Genomics develops and licenses AI/ML-powered bioinformatics platforms—Curo46™, CuroSygnal, and SYN46™—that combine proprietary genomic datasets, machine learning models, and large language models to deliver predictive analytics, return-to-hospital risk scoring, synthetic patient data generation, and decision-support insights for government agencies and commercial healthcare and pharmaceutical organizations. The platforms address disease susceptibility prediction, biosecurity threat assessment, and supply chain risk management with HIPAA, GDPR, and FDA 21 CFR Part 11 compliance built in.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

General Genomics Inc. offers a platform-plus-modules architecture centered on three core products: Curo46™ (AI-powered analytics platform), CuroSygnal (explainable AI clinical decision support), and SYN46™ (synthetic data/virtual patient models). These are complemented by specialized solutions including EdTech training programs, a Data Portal for synthetic data access, Custom Data Solutions, and NAICS code services. The platform serves both government (national security, public health, bioinformatics) and commercial (pharmaceuticals, insurance, research, sports medicine) sectors with AI/ML-driven predictive analytics, data governance, and bioinformatics solutions.

Product and service7 records
1Curo46™
CategoryAI/ML Predictive Analytics Platform
Description

Flagship AI/ML analytics platform that uses proprietary genomic and biological datasets plus LLMs to deliver predictive analytics, real-time dashboards, and actionable insights for disease detection, biosecurity threat assessment, supply chain risk management, and operational readiness across government and commercial clients.

2CuroSygnal
CategoryClinical Decision Support Software
Description

Explainable AI clinical decision-support platform for skilled nursing and post-acute care teams that surfaces residents with elevated return-to-hospital risk 3-14 days in advance, featuring Hot Rack ranked patient queues, trend forecasting, and feature-level explainability. Native to MatrixCare EHR with Microsoft SSO authentication.

3SYN46™
CategorySynthetic Data Platform
Description

Synthetic data solution that generates virtual patient models and downloadable datasets simulating individual health trajectories for disease prediction, preparedness, and privacy-compliant research and analytics across healthcare, government, and bioinformatics sectors.

4EdTech and Professional Development
CategoryProfessional Training and Education
Description

Training and workforce development services offering AI/ML integration workshops, custom training programs, and sector-specific professional development for government and commercial professionals.

5Data Portal
CategoryData Access Platform
Description

Secure, compliant data portal providing access to synthetic and de-identified datasets, enabling businesses to request tailored data solutions across healthcare, government, and bioinformatics sectors.

6Custom Data Solutions
CategoryCustom Analytics Services
Description

Tailored data solutions combining advanced analytics, machine learning, and custom tools to optimize workflows, improve data accuracy, and predict outcomes for pharmaceuticals, insurance, and research organizations.

7De-Identified Data
CategoryDe-Identified Data Products
Description

Safeguarded de-identified data solutions that maximize data usability for advanced research and analytics while protecting privacy compliance, enabling secure sharing and analysis across industries.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-focused AI/ML predictive analytics platform that builds risk models (including hospital readmission) for payers, providers, and ACOs. Closest direct competitor to General Genomics on the predictive-health risk and post-acute analytics side of the business.

TypeDirect peer
Description

Provider of synthetic healthcare data derived from real patient records for privacy-preserving research and analytics. Directly comparable to General Genomics' SYN46 synthetic data product and Data Portal offering.

TypeDirect peer
Description

Synthetic de-identified healthcare data platform used by health systems, payers, and life sciences companies for analytics and research. Overlaps with General Genomics' SYN46 and de-identified data products for healthcare and pharma use cases.

4Tempus AI
TypeBroad incumbent
Description

Large AI-powered precision medicine company combining genomic sequencing, multi-omics, and clinical data for oncology and broader healthcare. Broad incumbent in AI genomics and predictive analytics that competes with General Genomics' Curo46 platform at much larger scale.

TypeBroad incumbent
Description

Healthcare intelligence platform using AI over de-identified patient data for life sciences, payers, and providers. Broader incumbent in healthcare AI/data analytics overlapping with General Genomics' predictive and synthetic-data use cases.

TypeBroad incumbent
Description

AI-for-biology company building federated learning and multimodal models for pharma research and clinical trials. Comparable to General Genomics' bioinformatics and pharma R&D offerings at a more established scale.

TypeBroad incumbent
Description

Real-world evidence analytics platform for biopharma, regulators, and payers, leveraging de-identified patient data. Comparable to General Genomics' commercial-sector analytics and de-identified data products serving pharma and insurance.

TypeBroad incumbent
Description

Healthcare data and analytics platform serving health systems with population health, risk, and operational analytics. Broad incumbent overlapping with General Genomics' healthcare and government analytics offerings.

TypeEmerging player
Description

AI/ML-based operational analytics for hospitals and health systems, including capacity and patient-flow optimization. Adjacent to General Genomics' predictive analytics, with overlap on health system buyer personas.

TypeOthers
Description

Healthcare data connectivity and de-identification infrastructure that links records across providers, payers, and life sciences. Enabling/ecosystem peer to General Genomics' synthetic and de-identified data strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

General Genomics Inc.

AI/ML Bioinformatics Softwareggenomics.com

What General Genomics Inc. does

General Genomics Inc. is a privately held, Service-Disabled Veteran-Owned Small Business founded in 2020 and headquartered in Oklahoma City, with a wholly-owned subsidiary (General Genomics AI / GGAI) in Fort Worth, TX. The company develops AI/ML-powered bioinformatics software that combines proprietary machine learning models, large language models, predictive analytics, and synthetic data generation to analyze biological and man-made systems for government and commercial clients. Its product portfolio centers on three core platforms: Curo46™, an AI analytics platform for predictive health risk management, biosecurity threat assessment, and operational readiness; CuroSygnal, an explainable AI clinical decision support tool deployed in skilled nursing and post-acute care to surface return-to-hospital risk 3-14 days in advance; and SYN46™, which generates virtual patient models and downloadable de-identified datasets for privacy-compliant research and analytics. The company also offers EdTech and professional development training, a forthcoming Data Portal for synthetic data distribution, custom informatics solutions, and NAICS-aligned federal procurement services.

The firm pursues a direct enterprise sales motion targeting federal, state, and local government agencies (across DOD, HHS, DHS, Intel Community, USDA, FDA, and NASA) alongside commercial customers in healthcare providers, pharmaceuticals, insurance, sports medicine, and academic research. It relies on SDVOSB set-aside procurement advantages, NAICS code alignment, and compliance postures covering HIPAA, GDPR, and FDA 21 CFR Part 11 (clinical decision support exemption). CuroSygnal is natively integrated with the MatrixCare EHR and supports Microsoft single sign-on.

General Genomics generates revenue through platform licensing and subscriptions (Curo46™, CuroSygnal), synthetic and de-identified data products (SYN46™, forthcoming Data Portal), and professional services including custom AI/ML integration and workforce training. The company has raised approximately $4.95M across three funding rounds (2020, 2021, May 2024), holds one granted U.S. patent plus two pending patents on ML-driven disease prediction and treatment recommendation, and operates with an 11-50 employee team led by CEO & Founder AJ Rosenthal, COO & VP of Growth & EdTech Dr. Chris Naler (Col. USMC Ret.), and Director of Machine Learning Dr. Shannon Schlueter.

General Genomics Inc. firmographics

Firmographics
Name
General Genomics Inc.
Legal name
General Genomics, Inc.
Website
https://ggenomics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

General Genomics Inc. industry classification

Industry
Product category
AI/ML Bioinformatics Software
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs

Keywords

  • Predictive analytics
  • Synthetic data
  • Bioinformatics platforms
  • Clinical decision support
  • Genomic risk prediction

Where General Genomics Inc. is headquartered

Location

Headquarters

HQ city
Oklahoma City
HQ country
United States
HQ region
North America

Offices2 records

Markets served

General Genomics Inc. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI/ML Platform Licensing and Subscriptions: Revenue generated from licensing proprietary AI platforms including Curo46™ and CuroSygnal to government and commercial clients. Solutions are tailored to organization-specific needs with custom implementation and ongoing support.
  2. Synthetic and De-identified Data Products: Revenue from providing synthetic data (SYN46™) and de-identified datasets through the Data Portal for healthcare, research, and commercial applications.
  3. Professional Services and Consulting: Custom AI/ML integration, workflow optimization, and professional development training services. Includes sector-specific training programs for government and commercial sectors.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goDemo evaluation available

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

General Genomics Inc. product offering

Product offering

Core offering

General Genomics develops and licenses AI/ML-powered bioinformatics platforms—Curo46™, CuroSygnal, and SYN46™—that combine proprietary genomic datasets, machine learning models, and large language models to deliver predictive analytics, return-to-hospital risk scoring, synthetic patient data generation, and decision-support insights for government agencies and commercial healthcare and pharmaceutical organizations. The platforms address disease susceptibility prediction, biosecurity threat assessment, and supply chain risk management with HIPAA, GDPR, and FDA 21 CFR Part 11 compliance built in.

Product overview

General Genomics Inc. offers a platform-plus-modules architecture centered on three core products: Curo46™ (AI-powered analytics platform), CuroSygnal (explainable AI clinical decision support), and SYN46™ (synthetic data/virtual patient models). These are complemented by specialized solutions including EdTech training programs, a Data Portal for synthetic data access, Custom Data Solutions, and NAICS code services. The platform serves both government (national security, public health, bioinformatics) and commercial (pharmaceuticals, insurance, research, sports medicine) sectors with AI/ML-driven predictive analytics, data governance, and bioinformatics solutions.

Differentiator

Problem solved

Functional benefit

Brands

  • Curo46™: AI-powered platform designed to drive innovation in bioscience and data solutions, providing predictive health risk management, supply chain optimization, and advanced cybersecurity measures.
  • CuroSygnal
  • SYN46™
  • General Genomics AI (GGAI)

Products and services

  • Curo46™ Flagship AI/ML analytics platform that uses proprietary genomic and biological datasets plus LLMs to deliver predictive analytics, real-time dashboards, and actionable insights for disease detection, biosecurity threat assessment, supply chain risk management, and operational readiness across government and commercial clients.
  • CuroSygnal Explainable AI clinical decision-support platform for skilled nursing and post-acute care teams that surfaces residents with elevated return-to-hospital risk 3-14 days in advance, featuring Hot Rack ranked patient queues, trend forecasting, and feature-level explainability. Native to MatrixCare EHR with Microsoft SSO authentication.
  • SYN46™ Synthetic data solution that generates virtual patient models and downloadable datasets simulating individual health trajectories for disease prediction, preparedness, and privacy-compliant research and analytics across healthcare, government, and bioinformatics sectors.
  • EdTech and Professional Development Training and workforce development services offering AI/ML integration workshops, custom training programs, and sector-specific professional development for government and commercial professionals.
  • Data Portal Secure, compliant data portal providing access to synthetic and de-identified datasets, enabling businesses to request tailored data solutions across healthcare, government, and bioinformatics sectors.
  • Custom Data Solutions Tailored data solutions combining advanced analytics, machine learning, and custom tools to optimize workflows, improve data accuracy, and predict outcomes for pharmaceuticals, insurance, and research organizations.
  • De-Identified Data Safeguarded de-identified data solutions that maximize data usability for advanced research and analytics while protecting privacy compliance, enabling secure sharing and analysis across industries.

Companies that use General Genomics Inc.

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

General Genomics Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature4 records

General Genomics Inc. partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

General Genomics Inc. competitors and assessment

Company assessment

Direct peers

  • ClosedLoop.ai: Healthcare-focused AI/ML predictive analytics platform that builds risk models (including hospital readmission) for payers, providers, and ACOs. Closest direct competitor to General Genomics on the predictive-health risk and post-acute analytics side of the business.
  • Syntegra: Provider of synthetic healthcare data derived from real patient records for privacy-preserving research and analytics. Directly comparable to General Genomics' SYN46 synthetic data product and Data Portal offering.
  • MDClone: Synthetic de-identified healthcare data platform used by health systems, payers, and life sciences companies for analytics and research. Overlaps with General Genomics' SYN46 and de-identified data products for healthcare and pharma use cases.

Broad incumbents

  • Tempus AI: Large AI-powered precision medicine company combining genomic sequencing, multi-omics, and clinical data for oncology and broader healthcare. Broad incumbent in AI genomics and predictive analytics that competes with General Genomics' Curo46 platform at much larger scale.
  • Komodo Health: Healthcare intelligence platform using AI over de-identified patient data for life sciences, payers, and providers. Broader incumbent in healthcare AI/data analytics overlapping with General Genomics' predictive and synthetic-data use cases.
  • Owkin: AI-for-biology company building federated learning and multimodal models for pharma research and clinical trials. Comparable to General Genomics' bioinformatics and pharma R&D offerings at a more established scale.
  • Aetion: Real-world evidence analytics platform for biopharma, regulators, and payers, leveraging de-identified patient data. Comparable to General Genomics' commercial-sector analytics and de-identified data products serving pharma and insurance.
  • Health Catalyst: Healthcare data and analytics platform serving health systems with population health, risk, and operational analytics. Broad incumbent overlapping with General Genomics' healthcare and government analytics offerings.

Emerging players

  • LeanTaaS: AI/ML-based operational analytics for hospitals and health systems, including capacity and patient-flow optimization. Adjacent to General Genomics' predictive analytics, with overlap on health system buyer personas.

Others

  • Datavant: Healthcare data connectivity and de-identification infrastructure that links records across providers, payers, and life sciences. Enabling/ecosystem peer to General Genomics' synthetic and de-identified data strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

General Genomics Inc. social profiles

Digital presence

General Genomics Inc. compliance and trust

Trust signal

Compliance3 records

General Genomics Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

General Genomics Inc. leadership team

Management profile

Number of profiles

Profiles6 records

General Genomics Inc. subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

General Genomics Inc. funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

General Genomics Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about General Genomics Inc.

What does General Genomics Inc. do?

General Genomics develops and licenses AI/ML-powered bioinformatics platforms—Curo46™, CuroSygnal, and SYN46™—that combine proprietary genomic datasets, machine learning models, and large language models to deliver predictive analytics, return-to-hospital risk scoring, synthetic patient data generation, and decision-support insights for government agencies and commercial healthcare and pharmaceutical organizations. The platforms address disease susceptibility prediction, biosecurity threat assessment, and supply chain risk management with HIPAA, GDPR, and FDA 21 CFR Part 11 compliance built in.

Is General Genomics Inc. a public or private company?

General Genomics Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was General Genomics Inc. founded?

General Genomics Inc. was founded in 2020. It employs 11 to 50 people.

Where is General Genomics Inc. based?

General Genomics Inc. is headquartered in Oklahoma City, United States, in the North America region.

How does General Genomics Inc. make money?

Three revenue lines are on record. AI/ML Platform Licensing and Subscriptions are the primary driver. The others are synthetic and De-identified Data Products and professional Services and Consulting.

Who are General Genomics Inc.'s main competitors?

Direct peers on record are ClosedLoop.ai, Syntegra and MDClone. Broad incumbents are Tempus AI, Komodo Health, Owkin, Aetion and Health Catalyst. LeanTaaS is listed as an emerging player. Datavant is listed as an others.

Does General Genomics Inc. have an API?

No public API is recorded for General Genomics Inc..

What industry is General Genomics Inc. in?

General Genomics Inc.'s product category is AI/ML Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OKC VeloCityMomentum builds for Oklahoma’s life sciences sectorLife Science Oklahoma (LSOK) reported a 25% increase in membership over the past year and launched its inaugural Catalyst event, drawing more than 100 attendees from the life sciences and technology sectors. The organization facilitated over $2.7 million in collective savings for member companies through the Bio Business Solutions purchasing program and helped connect local AI company General Genomics with a partnership enabling its platform launch on the Microsoft marketplace. LSOK also participated in the BIO International Convention to promote Oklahoma's bioscience capabilities to industry professionals and investors.PR NewswireMoleculera Labs and General Genomics Form Strategic Alliance to Utilize Proprietary AI to Provide Personalized Medicine for Autoimmune Neuropsychiatric DisordersMoleculera Labs and General Genomics have formed a strategic alliance to combine GGI's Curo46 AI engine with Moleculera's autoimmune neuropsychiatric patient data and Cunningham Panel diagnostic tests. The partnership aims to help physicians predict treatment efficacy for conditions like PANDAS and PANS using machine learning analysis of patient outcomes. General Genomics was founded by former General Electric and Baker Hughes AI engineers, bringing patent-pending healthcare ML and AI innovations to direct individualized healthcare.Futurology69 Most Innovative Texas Based Predictive Analytics CompaniesA list of 69 Texas-based predictive analytics companies is presented, covering startups and established brands. The companies are selected for innovation, growth, management, societal impact, or performance, with descriptions of their services.Startupill69 Best Predictive Analytics Startups in Texas of 2021A curated list of 69 Texas-based predictive analytics startups is presented, covering companies from startups to established brands. The selection criteria include innovation, growth, and societal impact, with descriptions of each company's focus area.10 Best DNA Test Kits in 2024 (AncestryPersonalizing Healthcare Through Data With General GenomicsGeneral Genomics, founded in March 2020 by AJ Rosenthal and Warren Gieck, offers an AI platform for analyzing disease susceptibility and treatment effectiveness. The company holds two patents, one for disease susceptibility and another for survivability with different treatments. They advocate for patients to control their own health data.Startupill20 Best Genetics Startups Worth A Follow In 2021The article profiles 20 genetics startups, including Taysha Gene Therapies, General Genomics, and FerGene, covering gene therapy, diagnostics, and synthetic biology. It highlights their innovations, growth, and societal impact, with data sourced from Crunchbase and SemRush.of the Community RoundWe are Live on WeFunder!General Genomics Inc. announced its launch on WeFunder on December 10, 2020, with the public opening scheduled for December 24, 2020. The company is seeking funding for its Curo46 project, led by AJ Rosenthal, president of the company.Startupill20 Bioinformatics Startups Innovating The Industry In 2020Welp Magazine highlights 20 bioinformatics startups for their innovation, growth, and societal impact. The list includes companies like PetDx, JADBio, and Jiva, each with a brief description and headquarters location.